|
rs77375493
|
|
Autoimmune thrombocytopenia
|
|
0.010 |
GeneticVariation
|
BEFREE |
JAK2 V617F-positive essential thrombocythemia with subsequent development of immune thrombocytopenia: A case report.
|
31689837 |
2019 |
|
rs77375493
|
|
Petechiae of skin
|
|
0.010 |
GeneticVariation
|
BEFREE |
A 70-year-old woman with a five-year history of ET with JAK2 V617F mutation treated with hydroxycarbamide for five months presented with petechiae on her limbs.
|
31689837 |
2019 |
|
rs77375493
|
|
Inflammatory Bowel Diseases
|
|
0.010 |
GeneticVariation
|
BEFREE |
Moreover, despite the absence of JAK2 V617F mutation in patients with IBD, the increased gene expression of JAK2 can be explained by another molecular mechanism such as regulation of gene expression at the transcriptional level which may play crucial roles in the pathogenesis of IBD.
|
31069840 |
2019 |
|
rs77375493
|
|
Monocytosis
|
|
0.010 |
GeneticVariation
|
BEFREE |
We conclude that besides morphology of megakaryocytes and other features, JAK2 V617F allelic burden can help differentiate CMML from PMF with monocytosis.
|
30447300 |
2019 |
|
rs77375493
|
|
Breast Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Molecular analysis of V617F mutation in Janus kinase 2 gene of breast cancer patients.
|
31516339 |
2019 |
|
rs77375493
|
|
Thrombocytopenia due to platelet alloimmunization
|
|
0.010 |
GeneticVariation
|
BEFREE |
JAK2 V617F-positive essential thrombocythemia with subsequent development of immune thrombocytopenia: A case report.
|
31689837 |
2019 |
|
rs77375493
|
|
Immune thrombocytopenic purpura
|
|
0.010 |
GeneticVariation
|
BEFREE |
JAK2 V617F-positive essential thrombocythemia with subsequent development of immune thrombocytopenia: A case report.
|
31689837 |
2019 |
|
rs77375493
|
|
Arteriopathic disease
|
|
0.010 |
GeneticVariation
|
BEFREE |
The current study describes rare cases of SAH accompanied by ischemic stroke secondary to ET along with a review of the current literature, implying specific mechanisms for cerebral artery disorders associated with JAK2 V617F mutation.
|
31049728 |
2019 |
|
rs77375493
|
|
Petechiae
|
|
0.010 |
GeneticVariation
|
BEFREE |
A 70-year-old woman with a five-year history of ET with JAK2 V617F mutation treated with hydroxycarbamide for five months presented with petechiae on her limbs.
|
31689837 |
2019 |
|
rs77375493
|
|
Malignant neoplasm of breast
|
|
0.010 |
GeneticVariation
|
BEFREE |
Molecular analysis of V617F mutation in Janus kinase 2 gene of breast cancer patients.
|
31516339 |
2019 |
|
rs77375493
|
|
Hypertension, Renovascular
|
|
0.010 |
GeneticVariation
|
BEFREE |
Evaluations revealed right renal artery stenosis causing renovascular hypertension and polycythemia vera with JAK2 V617F mutation.
|
29656438 |
2018 |
|
rs77375493
|
|
Heparin-induced thrombocytopenia
|
|
0.010 |
GeneticVariation
|
BEFREE |
Our data show that HIT is more frequent, during heparin treatment, in patients with ET carrying V617F mutation, as compared with patients without mutations (P = 0.029).
|
29022213 |
2018 |
|
rs77375493
|
|
Trigeminal Neuralgia
|
|
0.010 |
GeneticVariation
|
BEFREE |
There was no significant difference in the occurrence of thrombotic events among CARL-mutant, JAK2 V617F-mutant and TN patients.
|
29725364 |
2018 |
|
rs77375493
|
|
Pancreatic carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
The expanding scope of creative impact is perhaps most startling-from NCI-funded built environments to AACR Team Science Awarded studies of Asian cancer genomes informing global primary prevention policies; cell-free epigenetic marks identifying incipient neoplastic site; practice-changing genomic subclasses in myeloproliferative neoplasia (including germline variant tightly linked to JAK2 V617F haplotype); universal germline genetic testing for pancreatic cancer; and repurposing drugs targeting immune- and stem-cell signals (e.g., IL-1β, PD-1, RANK-L) to cancer interception.
|
30530635 |
2018 |
|
rs77375493
|
|
Heparin-induced thrombocytopenia with thrombosis
|
|
0.010 |
GeneticVariation
|
BEFREE |
High prevalence of heparin induced thrombocytopenia with thrombosis among patients with essential thrombocytemia carrying V617F mutation.
|
29022213 |
2018 |
|
rs77375493
|
|
Malignant neoplasm of pancreas
|
|
0.010 |
GeneticVariation
|
BEFREE |
The expanding scope of creative impact is perhaps most startling-from NCI-funded built environments to AACR Team Science Awarded studies of Asian cancer genomes informing global primary prevention policies; cell-free epigenetic marks identifying incipient neoplastic site; practice-changing genomic subclasses in myeloproliferative neoplasia (including germline variant tightly linked to JAK2 V617F haplotype); universal germline genetic testing for pancreatic cancer; and repurposing drugs targeting immune- and stem-cell signals (e.g., IL-1β, PD-1, RANK-L) to cancer interception.
|
30530635 |
2018 |
|
rs77375493
|
|
Pulmonary congestion
|
|
0.010 |
GeneticVariation
|
BEFREE |
TN patients had a significantly lower incidence of clinical symptoms, including dizziness, palpitation and chest congestion compared with CALR- or JAK2 V617F-mutant patients (14.1 vs. 39.1%; P=0.043 and 14.1 vs. 38.1%; P=0.050).
|
29725364 |
2018 |
|
rs77375493
|
|
Renal Artery Stenosis
|
|
0.010 |
GeneticVariation
|
BEFREE |
Evaluations confirmed left renal artery stenosis and essential thrombocythemia with JAK2 V617F.Angioplasty cured the hypertension.
|
29656438 |
2018 |
|
rs77375493
|
|
Sagittal Sinus Thrombosis
|
|
0.010 |
GeneticVariation
|
BEFREE |
Sagittal sinus thrombosis in JAK2-V617F mutation without overt myeloproliferative disorder.
|
28228434 |
2017 |
|
rs77375493
|
|
Acquired von Willebrand's disease
|
|
0.010 |
GeneticVariation
|
BEFREE |
Among ET patients, JAK2 V617F was a main driver for the development of AVWS.
|
27919526 |
2017 |
|
rs77375493
|
|
Toxic Epidermal Necrolysis
|
|
0.010 |
GeneticVariation
|
BEFREE |
26 (39%) of 66 haematological responders and 25 (71%) of 35 molecular responders (with the JAK2 Val617Phe mutation) have maintained some response during follow-up: 49% maintained their best molecular response (nine of ten patients who had a complete response, five of 20 who had a partial response, and three of five who had a minor response).
|
28291640 |
2017 |
|
rs77375493
|
|
Non-Small Cell Lung Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Further analysis of TCGA genomic data revealed JAK2 gain or loss due to genetic alterations in NSCLC clinical samples are associated with significantly elevated or reduced PD-L1 expression, suggesting that the activating JAK2 p.V617F mutation could confer sensitivity to both JAK inhibitors and anti-PD1 immunotherapy.
|
29082853 |
2017 |
|
rs77375493
|
|
Adenocarcinoma of lung (disorder)
|
|
0.010 |
GeneticVariation
|
BEFREE |
JAK2 V617F and N30S mutations and JAK2 amplification were detected by NGS in plasmid samples in patients with lung adenocarcinoma.
|
28639892 |
2017 |
|
rs77375493
|
|
Malignant neoplasm of duodenum
|
|
0.010 |
GeneticVariation
|
BEFREE |
This report presents a case of a JAK2 V617F mutation falsely identified as a duodenal cancer mutation via NGS.
|
27956534 |
2016 |
|
rs77375493
|
|
Liver Failure, Acute
|
|
0.010 |
GeneticVariation
|
BEFREE |
Here, a 22 year old female with angiographically proven BCS secondary to JAK2/V617F positive Polycythemia vera on therapeutic warfarin presented with acute liver failure (ALF).
|
26626649 |
2016 |